Cencora Secures $4.5B Term Loans & Boosts Revolving Credit for OneOncology Acquisition
Summary
Cencora, Inc. secured $4.5 billion in new term loan facilities and increased its revolving credit facility by $1.0 billion to $5.5 billion, funding a previously announced acquisition and replacing bridge financing.
Key Events
-
New Term Loan Facilities Secured
Cencora entered into a multi-year term loan facility of $1.5 billion (Tranche One: $500M, 2-year maturity; Tranche Two: $1.0B, 3-year maturity) and a 364-day term credit facility of $3.0 billion. These facilities total $4.5 billion and will be used to fund a portion of the previously announced acquisition of OneOncology and repay existing debt of OneOncology.
-
Revolving Credit Facility Increased
The company amended its existing revolving credit facility, increasing the aggregate commitments by $1.0 billion to a total of $5.5 billion.
-
Bridge Financing Replaced
The $4.5 billion in previously obtained bridge financing commitments for the acquisition have been automatically reduced to zero, replaced by the new term loan facilities.
-
Acquisition Funding
The proceeds from the new term loans are specifically earmarked to pay a portion of the consideration for the OneOncology acquisition and to refinance existing debt of the acquired entity.
Analysis
Cencora has successfully secured substantial financing to support its strategic acquisition of OneOncology. The new $4.5 billion in term loan facilities, coupled with a $1.0 billion increase in its revolving credit facility, significantly bolsters the company's liquidity and financial flexibility. The replacement of bridge financing with these definitive agreements is a positive development, reducing uncertainty around the acquisition's funding structure. This indicates strong lender confidence in Cencora's financial health and strategic direction, despite the increase in overall indebtedness.
At the time of this filing, COR was trading at $356.36 on NYSE in the Trade & Services sector, with a market capitalization of approximately $69.1B. The 52-week trading range was $237.71 to $377.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.